European Regulators Unexpectedly Recommend Acadia Pharma's Rett Syndrome Drug, Stock Jumps

Key Facts

In a positive development for the biotech sector, European regulators unexpectedly recommended approval of Acadia Pharma's Rett syndrome drug Daybu, causing the company's stock to rise on Friday. The recommendation marks a surprising reversal from the European Medicines Agency (EMA), which had previously rejected similar treatments.

The EMA's recommendation comes after Acadia had faced a setback in 2024 when the agency initially declined the drug. Daybu could become the first approved treatment for Rett syndrome in Europe, a rare neurological disorder primarily affecting girls. Per market data, the stock rose over 7% in recent trading.

On June 26, ACAD shares traded around $27.50, posting strong daily gains. While no immediately impactful economic events appear on the calendar, investors are awaiting the EMA's final decision in the coming months, which could open access to a market valued at over $1 billion annually.